Search
Gallium maltolate
go.drugbank.com/drugs/DB05420InvestigationalGallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.
Dexamethasone acetate
go.drugbank.com/drugs/DB14649ApprovedInvestigationalVet approvedone-fifth and one-third in patients on oxygen therapy and mechanical ventilation, respectively. … [L10701] Recently, dexamethasone has been a drug of interest in the treatment of COVID-19.
Mixtures: BAYCUTEN® N CREMA, BAYCUTEN® N CREMAOxyfedrine
go.drugbank.com/drugs/DB13398ExperimentalCategories: Vasodilators Used in Cardiac Diseases, Compounds used in a research, industrial, or household settingDiosmetin
go.drugbank.com/drugs/DB11259ApprovedDiosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231].
SNS-314
go.drugbank.com/drugs/DB06134InvestigationalSNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.
Coltuximab ravtansine
go.drugbank.com/drugs/DB06342InvestigationalColtuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).
Typhoid Vi polysaccharide vaccine
go.drugbank.com/drugs/DB10803ApprovedInvestigationalIt is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. … The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.
Products: Typhim VI Solution for Injection in Multidose, Typhim Vi Injektionslösung in einer FertigspritzeOrnithine
go.drugbank.com/drugs/DB00129ApprovedInvestigationalNutraceuticalProduced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine.
Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSIONRotavirus vaccine
go.drugbank.com/drugs/DB10276ApprovedInvestigational[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.[L1117]
Categories: Complex MixturesCCX915
go.drugbank.com/drugs/DB05159ExperimentalCCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.